Bortezomib a safety treatment for patients with Multiple Myeloma and Cystic Fibrosis

Fabiana Gentilini, Anna Levi, Vincenzo Federico, Eleonora Russo, Robin Foà, Maria Teresa Petrucci
  • Anna Levi
    Dip. of Hematology, Sapienza University of Rome, Italy
  • Vincenzo Federico
    Dip. of Hematology, Sapienza University of Rome, Italy
  • Eleonora Russo
    Dip. of Hematology, Sapienza University of Rome, Italy
  • Robin Foà
    Dip. of Hematology, Sapienza University of Rome, Italy
  • Maria Teresa Petrucci
    Dip. of Hematology, Sapienza University of Rome, Italy

Abstract

Introduction: Bortezomib is a proteasome inhibitor that targets myeloma cell and its bone marrow micro-environment. Intravenous Bortezomib (1.3 mg/m2 administered on days 1,4,8 and 11 of a 21 day cycle), with or without dexamethasone, is effective and well tolerated in patients with relapsed/refractory multiple myeloma (MM).

Methods:  We treated a MM patient with Cystic Fibrosis with Bortezomib alone to avoid the use of corticosteroid and consequently the risk of lung infection reactivations, first of all due to the patient Pseudomonas aeruginosa colonization. Bortezomib was administrated at 1.3 mg/m2 on days 1,4,8 and 11 with a 10 day rest period  and four 21-day cycles were administered. We evaluate the treatment response and toxicity.

Results: After four cycles of therapy the patient achieved a  very good partial response (VGPR) according to the IMWG response criteria, without clinically significant side effects.

Conclusions: Bortezomib can be successfully utilized for the management of this difficult disease situation

Keywords

Multiple Myeloma, Cystic Fibrosis, Bortezomib

Full Text:

PDF
HTML
Submitted: 2014-06-13 09:33:20
Published: 2012-05-07 00:00:00
Search for citations in Google Scholar
Related articles: Google Scholar
Abstract views:
127

Views:
PDF
109
HTML
271

Article Metrics

Metrics Loading ...

Metrics powered by PLOS ALM


Copyright (c) 2016 Mediterranean Journal of Hematology and Infectious Diseases

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

 

The Mediterranean Journal of Hematology and Infectious Diseases [eISSN 2035-3006] is owned by the U.C.S.C. and it is published by PAGEPress®, Pavia, Italy. All credits and honors to PKP for their OJS.
 
 
© PAGEPress 2008-2017     -     PAGEPress is a registered trademark property of PAGEPress srl, Italy.     -     VAT: IT02125780185